The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Novel technologies in multiple myeloma and how these are changing the field
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, shares some insights into how novel technologies, including whole-genome and single-cell sequencing (WGS; SCS), are transforming the field of multiple myeloma and providing researchers and clinicians with a better understanding of the disease. Furthermore, these novel technologies are able to provide information on the role of the microbiome in myeloma, and allow clinicians to better understand patient response to novel immunotherapies. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
